Questions discussed in this category
Thrombophilia testing, including JAK2 is negative. When would you stop anticoagulation?
E.g., a patient with newly diagnosed CIDP who is wheelchair-bound.
Assume patient requires anticoagulation in the setting of acute thrombosis, with no need for IVC filter, but is approaching the end of her third trime...
What is your preferred anticoagulation in patients with BMI >50?
Are the INRs reliable? In what scenarios would you not recommend POC INR use for warfarin monitoring?
Are these typically covered by insurance? Are t...
Do you do additional workup for venous obstruction or any other different testing/evaluation?
Additional risk factors could be family history of VTE or thrombophilia, such as antithrombin deficiency.
Estimating blood loss from hemoptysis is not always reliable. The bleeding may be due to the PE itself. Is anticoagulation with any degree of hemoptys...
In the setting of requiring anticoagulation for atrial fibrillation and bioprosthetic valve, but also having severe vitamin K deficiency, would you st...
Is it different than early mobility that we always encourage?
Would you still plan for lifelong anticoagulation in this scenario?
E.g. young male, morbid obesity, with BMI >50
While follow up ultrasound is not usually recommended in provoked DVT, it often is done either for other reasons or by other physicians. Would this in...
I.e. platelet count <30. Would your management change if HIT were only suspected rather than confirmed?
What is the work up and what is the duration of anticoagulation if used?
Specifically, asymptomatic subsegmental PE diagnosed within a month from planned bilateral mastectomy for breast cancer.
Significant history of autoimmune diseases and DVT in family, recent PE/DVT for a month
Is patch or gel HRT with ASA prophylaxis a reasonable option after counseling? Or do you add a prophylactic DOAC?
Is lifelong LMWH the anticoagulant of choice? Would DOACs be an option?
Would you consider low dose indefinite anticoagulation in any scenario? Any difference in approach between hematological malignancy and solid tum...
No prior thrombosis; no family history of thrombosis. As per endocrine, the only useful therapy for the osteoporosis is estrogen.
E.g. pulmonary embolism, portal vein thrombosis, cerebral venous sinus thrombosis
Would the answer differ if the index event was arterial vs venous?
Previous provoking factors resolved (CVC, malignancy, etc)
If work-up is sent and the patient is found to have a persistently positive antiphospholipid antibody, particularly lupus anticoagulant, would you con...
Currently on nonwarfarin therapeutic anticoagulation
The patient has no personal history of VTE, but has positive family history of VTE.
Any prophylactic anticoagulation options?
How would manage...
Is it time limited since it may have been triggered by the pregnancy or is it indefinite since it is APLS associated?
I.e., what constitutes well-controlled cancer, IBD, nephrotic syndrome, etc. What other diseases do you put in this category (obesity, autoimmune dise...
i.e. long car rides or plane rides
- Dialysis catheter used for hemodialysis- RIJ thrombus in dialysis catheter was incidentally found- Patient asymptomatic with no prior history of VTE...
If so, what would you consider ordering?
Should we stop checking factor VIII levels as part of thrombosis workup?
FVL heterozygotes are often treated similarly to the general population. Aside from avoiding other VTE risk factors, are there situations where prophy...
How does cirrhosis and/or underlying thrombophilia affect your decision?
What should be done with a high level?
For example, for outpatients or resource-limited settings with a moderate probability 4-T score (but low clinical suspicion), would you ever consider ...
e.g. in the setting of using prophylactic heparin in the past but now requiring therapeutic anticoagulation
Would you offer indefinite anticoagulation if the event is unprovoked and the patient has low bleeding risk?
If so, what agent(s) do you prefer?
What is your duration of anticoagulation?
Provoked or unprovoked VTE: Do you use D-Dimer (or even repeat imaging to reassess residual clot) in any capacity to guide anticoagulation duration? E...
Is there data that it actually helps?
While there are many factors involving:- type (DVT vs PE, unprovoked vs provoked) and severity of venous thromboembolism (VTE) size- duration of antic...
Is there any difference between anticoagulants in this clinical context (e.g. anti-Xa inhibitors vs warfarin vs LMWH)?
Does having a concurrent consumptive process e.g. DIC change your management?
Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?
While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?
Ref: EINSTEIN-CHOICE and AMPLIFY-EXT
Would you approach this differently in patients with inherited thrombophilias?
Is there a preferred strategy of transfusional support versus reduced-dose anticoagulation during the duration of thrombocytopenia?
Would you offer this routinely or only if specific complications arise, such as distal emboli?
Would it make a difference if the VTE diagnosis occurs during bevacizumab therapy or whether it preceded the cancer diagnosis?
20757172111866520895164942070519438205741331919529194731908815962172751784618718185629388133001767418257129101815317970143181716513850167031729215755171311178616617165631565314813124491084812302148801481014842148168843139031370811218135119574108561295212692121418133106661200010958116191156911080889810990112769961110441097892861061410560875210082100319890984492639019854286758114780024507003
Papers discussed in this category
Acta Paediatr., 2020 Mar 23
Blood Transfus, 2018 Oct 24
J Thromb Haemost, 2018 May 08
J Vasc Interv Radiol, 2020 Sep 09
Blood, 2013-12-05
Blood Adv,
Blood,
Thrombosis, 2013
Thrombosis journal, 2023 Oct 26
PLoS One, 2021 Apr 08
N Engl J Med, 2021 Apr 14
J Natl Cancer Inst, 2011 Jul 09
Br J Clin Pharmacol, 2020 Jun 02
Semin Hematol,
Expert Rev Hematol, 2019 Jul 05
J Thromb Thrombolysis,
Blood advances, 2018-11-27
Blood advances, 2018-11-27
Autoimmun Rev, 2017 Sep 09
Blood Adv, 2017 Jun 22
Circulation, 2022 Nov 06
Circulation, 2022 Nov 06
Lancet,
Post reproductive health, 2022 Dec 27
J Thromb Haemost, 2021 Jul 14
Blood, 2020 Mar 19
Haematologica, 2019 Jan 03
The New England journal of medicine, 2013-02-21
The New England journal of medicine, 2017 Mar 18
Journal of hospital medicine, 2019-01
The New England journal of medicine, 2019 Feb 18
Phlebology, 2020 Mar 02
VASA. Zeitschrift fur Gefasskrankheiten, 2001 Jul
Journal of vascular surgery, 2000 Nov
Blood, 2014 Oct 15
Circulation. Cardiovascular interventions, 2015-10
Research and practice in thrombosis and haemostasis, 2018 Oct 19
Thrombosis and haemostasis, 2019 Oct 28
Journal of thrombosis and haemostasis : JTH, 2021 Apr 01
Journal of medical case reports, 2014 Mar 04
Circulation, 2011-12-20
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013-01
American journal of nephrology, 2013
Journal of the American Heart Association, 2021 Jun 26
Autoimmunity reviews, 2017 Feb 13
Thrombosis research, 2023 Feb 10
Lupus, 2017 Mar 29
Respirology (Carlton, Vic.), 2018 Jul 16
Journal of thrombosis and haemostasis : JTH, 2019 Sep 13
The Journal of clinical endocrinology and metabolism, 2024 Jan 18
Stroke, 2023 Sep 07
Stroke, 2024 Jan 29